Dyspepsia, upper gastrointestinal tract disease Digestive System Dyspepsia
Conditions
Interventions
Active: Lansoprazole 30 mg per day, once per day, per oral, for 14 days. Follow up for 14 days.
Control: Placebo, once per day, per oral, for 14 days. Follow up for 14 days.
Sponsors
University of Glasgow (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Upper gastrointestinal (GI) symptoms of more than 3 months duration 2. No evidence of peptic ulcer disease, erosive oesophagitis or hiatus hernia in endoscopy 3. H. pylori negative on histology and urease test 4. Aged 24 - 72 years, either sex
Exclusion criteria
Exclusion criteria: 1. Current use of non-steroidal anti-inflammatory drugs or other medication 2. Any recognised cause of upper GI symptoms
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in overall symptom score measured by modified Glasgow Dyspepsia Severity Score. All these measurements will be taken on baseline and at the end of 2 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Predictors of response to lansoprazole including symptom severity score, symptom characteristics, oesophageal 24h pH metry and oesophageal manometry profiles and body mass index (BMI). All these measurements will be taken on baseline. | — |
Countries
United Kingdom
Outcome results
None listed